Evidence map›Paper›PMID 41910486›Full record

ArticleKidney3602026

Dysregulated Protease Homeostasis Defines Primary FSGS.

Johannes Schmidt, Nina Sopel, Carmen Rist, Alexandra Ohs, Laura Dawid, Stefan Simm, Lorenzo Catanese, Harald Rupprecht, Tilman Jobst-Schwan, Jörg Lehmann and 4 more

Abstract read
In one paragraph

Article in Kidney360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Johannes SchmidtDepartment of Preclinical Development and Validation, Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany.ORCID 0000-0002-2026-9715
Nina SopelDepartment of Nephrology and Hypertension, Uniklinikum Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany.
Carmen RistDepartment of Nephrology and Hypertension, Uniklinikum Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany.ORCID 0009-0008-4906-0123
Alexandra OhsDepartment of Nephrology and Hypertension, Uniklinikum Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany.ORCID 0000-0001-9409-9619
Laura DawidDepartment of Preclinical Development and Validation, Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany.
Stefan SimmInstitute for Bioanalysis, University of Applied Sciences Coburg, Coburg, Germany.ORCID 0000-0001-9371-2709
Lorenzo CataneseDepartment of Nephrology, Angiology and Rheumatology, Klinikum Bayreuth GmbH, Bayreuth, Germany.ORCID 0000-0002-9933-8364
Harald RupprechtDepartment of Nephrology, Angiology and Rheumatology, Klinikum Bayreuth GmbH, Bayreuth, Germany.
Tilman Jobst-SchwanDepartment of Nephrology and Hypertension, Uniklinikum Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany.ORCID 0000-0001-9802-6783
Jörg LehmannDepartment of Preclinical Development and Validation, Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany.ORCID 0000-0001-8560-648
Christoph DanielDepartment of Nephropathology, Uniklinikum Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany.ORCID 0000-0002-6803-4755
Stefan KalkhofDepartment of Preclinical Development and Validation, Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany.ORCID 0000-0001-6121-7105
Mario SchifferDepartment of Nephrology and Hypertension, Uniklinikum Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany.ORCID 0000-0002-8414-1470
Janina Müller-DeileDepartment of Nephrology and Hypertension, Uniklinikum Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany.ORCID 0000-0001-6081-5664

Funding

Bundesministerium für Bildung und Forschung 01GM2202DDeutsche Forschungsgemeinschaft 509149993Else Kröner-Fresenius-Stiftung 01ZX2210BElse Kröner-Fresenius-Stiftung 2019_KollegSE.04KidneySign 01KU2305Urinproteom-Analyse für die Prädiktion von Typ, Ausmaß, Prognose und therapeutischem Ansprechen von akuten und chronischen Nierenerkrankungen 01EK2105A
6 · The paper itself

Abstract

key pointsSerum proteomics reveals reduced serpin family A member 1 (SERPINA1) in primary FSGS, distinguishing it from other proteinuric kidney diseases. Serpina1 knockdown in zebrafish causes proteinuria and edema, supporting its functional relevance in glomerular disease. SERPINA1 may exert compartment-specific functions, and its decrease may permit protease activity to contribute to podocyte injury in primary FSGS.

backgroundPrimary FSGS (pFSGS) is caused by circulating permeability factors. Despite extensive efforts, no single causative factor or biomarker signature has been identified that reliably predicts disease or therapeutic outcomes across all patients. By using liquid chromatography-mass spectrometry-based proteomics on serum samples from patients with pFSGS, compared with controls, we aimed to identify disease-specific protein signatures.

methodsLiquid chromatography-mass spectrometry-based proteomics analysis was performed on 103 serum samples from 36 patients with pFSGS, 33 patients with other proteinuric diseases, and 34 healthy controls. Selected proteins found to be dysregulated in pFSGS were tested in cell culture experiments in immortalized human podocytes. Knockdown experiments were performed in zebrafish larvae, which were screened for proteinuria, edema, and podocyte marker expression. Immunofluorescent staining on zebrafish sections and patients' kidney biopsies was used to confirm findings.

resultsMass spectrometry of sera from patients revealed a set of 27 proteins specifically affected in pFSGS, including a dysbalance of proteases and protease inhibitors. A subset of younger pFSGS patients with frequent relapses showed a distinct serum protein profile based on 23 dysregulated proteins. From proteomics results, serpin family A member 1 (SERPINA1; α-1-antitrypsin) was selected for further investigations. Urinary SERPINA1 increased across nephrotic syndromes, whereas serum SERPINA1 reduction was specific to pFSGS, suggesting a distinct underlying pathophysiology involving immune modulation, increased protease activity, or systemic depletion. Glomerular SERPINA1 expression was selectively increased in sclerotic lesions, likely reflecting a local compensatory response to protease stress. Podocytes constitutively secreted SERPINA1, with limited adaptive response under protease stress. Finally, systemic Serpina1 knockdown in zebrafish induced edema, proteinuria, and loss of slit diaphragm markers.

conclusionsOur findings support a causal and compartment-specific role of SERPINA1 and suggest that reduced circulating protease inhibitors may shift the local protease-antiprotease balance, potentially facilitating podocyte injury in pFSGS.

Indexed as

alpha 1-AntitrypsinGlomerulosclerosis, Focal SegmentalPeptide HydrolasesAdultAnimalsBiomarkersFemaleGene Knockdown TechniquesHomeostasisHumansMaleMass SpectrometryPodocytesProteinuriaProteomicsZebrafishalpha 1-AntitrypsinBiomarkersPeptide HydrolasesbiomarkersFSGSnephrotic syndromeproteomics

Identifiers

PMID41910486
PMCPMC13065173

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.